Source comparison
CJC-1295 No DAC: Comparison of Study Durations and Findings
8 weeks 24 participants IGF-1 elevation 1.8× baseline IGF-1 increase 12% mild GI distress Short-term efficacy confirmed; no safety signals 12 weeks 42 participants Body composition (DEXA) 2.1 kg lean mass gain vs placebo 18% injection site reactions Anabolic e
This comparison does not assign a generated winner or score.
- 8 weeks
- 24 participants
- IGF-1 elevation
- 1.8× baseline IGF-1 increase
- 12% mild GI distress
- Short-term efficacy confirmed; no safety signals
- 12 weeks
- 42 participants
- Body composition (DEXA)
- 2.1 kg lean mass gain vs placebo
- 18% injection site reactions
- Anabolic effect present; tolerability acceptable
- 16 weeks
- 36 participants
- GH pulsatility preservation
- No trough suppression vs baseline
- 15% transient nausea
- Longest controlled trial; pituitary function unchanged
- 26 weeks (tesamorelin analog)
- 412 participants
- Visceral adipose tissue reduction
- 15% VAT reduction
- 22% mild injection site pain
- Related GHRH analog; sustained safety demonstrated
- The pattern across all documented trials: GH response remains intact, IGF-1 elevation is dose-dependent and sustained without progressive increase, and side effects are front-loaded (first 2–4 weeks) rather than cumulative. What's missing: cancer incidence tracking, cardiovascular event monitoring, glucose homeostasis disruption beyond 16 weeks, and any data on use exceeding six months in humans.